Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S Berek

Showing results (71-80 of 172) with videos related to

Pageof 18
Sort By:
Applied Pathology|January 1, 1987
Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervixY S Fu, J S Berek, L H Hilborne
Cancer Treatment and Research|June 10, 1998
Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancerY B Kim, K Ghosh, S Ainbinder, et al.
Journal of Minimally Invasive Gynecology|September 29, 2016
Impact of the 2014 FDA Warnings Against Laparoscopic Power MorcellationD Lum, J S Berek, F Sheikhi, et al.
Cancer|October 1, 1987
Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoidesE Brand, J S Berek, R K Nieberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2017
Cytoreductive surgery for ovarian cancer: quality assessmentA H Brand, P A DiSilvestro, J Sehouli, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 27, 2003
CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancerS Memarzadeh, S B Lee, J S Berek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
Advanced ovarian cancer. Tumour markersG J Rustin, M E van der Burg, J S Berek
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 1, 1996
Mixed mesodermal sarcoma of the ovary in a young patientJ M Fowler, L Nathan, R K Nieberg, et al.
Cancer Research|October 15, 1988
Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicityA Lichtenstein, C Spina, J S Berek, et al.
Investigational New Drugs|May 1, 1990
Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group studyW P McGuire, J A Blessing, J S Berek, et al.
Pageof 18

Showing results (71-80 of 172) with videos related to

Sort By:
Pageof 18
Applied Pathology|January 1, 1987
Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervixY S Fu, J S Berek, L H Hilborne
Cancer Treatment and Research|June 10, 1998
Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancerY B Kim, K Ghosh, S Ainbinder, et al.
Journal of Minimally Invasive Gynecology|September 29, 2016
Impact of the 2014 FDA Warnings Against Laparoscopic Power MorcellationD Lum, J S Berek, F Sheikhi, et al.
Cancer|October 1, 1987
Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoidesE Brand, J S Berek, R K Nieberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2017
Cytoreductive surgery for ovarian cancer: quality assessmentA H Brand, P A DiSilvestro, J Sehouli, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 27, 2003
CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancerS Memarzadeh, S B Lee, J S Berek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
Advanced ovarian cancer. Tumour markersG J Rustin, M E van der Burg, J S Berek
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 1, 1996
Mixed mesodermal sarcoma of the ovary in a young patientJ M Fowler, L Nathan, R K Nieberg, et al.
Cancer Research|October 15, 1988
Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicityA Lichtenstein, C Spina, J S Berek, et al.
Investigational New Drugs|May 1, 1990
Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group studyW P McGuire, J A Blessing, J S Berek, et al.
Pageof 18